CIK细胞治疗乳腺癌的临床疗效评估

目的观察细胞因子诱导的杀伤细胞（CIK细胞）体外细胞毒活性，并观察CIK细胞治疗乳腺癌的近期临床疗效、免疫学活性及副反应。方法35例乳腺癌患者经规范化治疗后，取外周血分离单个核细胞（PBMC），体外诱导出CIK细胞培养后，观察CIK细胞表型，用MTT法测体外细胞毒活性；所有患者均接受一定剂量的CIK细胞过继免疫治疗，观察其近期临床疗效、免疫反应、不良反应。结果35例患者中，完全缓解24例，部分缓解6例，病情稳定1例，近期有效率为85．71％，疾病控制率为88．57％，无肿瘤进展时间为2～31个月，中位无肿瘤进展时间为15个月。细胞毒活性检测结果显示，当效靶比为16：1时，CIK细胞体外细胞毒活性为77．06±11．62。与CIK细胞回输前相比，患者CD3^＋，CD4^＋，CD8^＋均有明显的升高（P〈0．001）。35例患者在输注CIK过程中1例出现一过性发热（37．5℃）反应。结论CIK细胞在乳腺癌免疫治疗中能诱导机体产生特异性的免疫反应，亦是新的杀伤肿瘤细胞的效应细胞，结合传统的手术和化疗，有较好的临床疗效。

The clinical research of cytokine-induced killer cells on the clinical immunotherapy for breast tumor

Objective To investigate the cytokine-induced killer cells(CIK cells) cytotoxic activity in vitro,and to observe the short-term clinical efficacy,immunological activity and side effects of CIK cells in treating breast tumor.Methods A total of 35 patients with breast malignancies were recorded with CIK cell therapy from July 2007 to March 2010.Peripheral blood mononuclear cells(PBMC) from patients with standard treatment protocols were induced to CIK cell in vitro,then phenotype of CIK cells were observed an...